Health Economics›Diffuse large B-cell lymphoma›Untreated randomized data

Untreated randomized data

Diffuse large B-cell lymphoma · 19 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pola-R-CHP Variant #01	—	R 133 248	21d	—	—	—	—	2
R-CHOP Variant #23	—	R 59 865	21d	—	—	—	—	7
R-Hyper-CVAD/R-MA Variant #01	—	R 22 261	—	—	—	—	—	—
R-MegaCHOP-14 Variant #01	—	R 16 021	14d	—	—	—	—	—
R2-CHOP Variant #01	—	R 14 839	21d	—	—	—	—	1
R-CEOP90 Variant #01	—	R 14 147	21d	—	—	—	—	2
R-CHOEP-14 Variant #01	—	R 13 714	14d	—	—	—	—	—
R-CEOP70 Variant #01	—	R 13 712	21d	—	—	—	—	1
R-miniCEOP Variant #01	—	R 13 325	21d	—	—	—	—	—
DA-R-EPOCH Variant #01	—	R 13 318	21d	—	—	—	—	1
R-CHOP (SC Rituximab) Variant #01 Partial	—	R 12 681	21d	—	—	—	—	—
R-CHOP-14 (Prednisolone) Variant #01	—	R 12 674	14d	—	—	—	—	1
R-CHOP-14 (SC Rituximab) Variant #01 Partial	—	R 12 667	14d	—	—	—	—	—
R-CHOP (Prednisolone) Variant #01	—	R 12 666	21d	~42.4 mo	—	~62	~R 785 263 PFS proxy · indirect	—
R-CHOP-14 Variant #01	—	R 12 661	14d	—	—	—	—	—
R-miniCHOP (SC Rituximab) Variant #01 Partial	—	R 12 226	21d	—	—	—	—	—
R-THP-COP Variant #01 Partial	—	R 12 195	21d	—	—	—	—	—
Hi-CHOP Variant #01 Partial	—	R 872	21d	—	—	—	—	—
R-ACVBP N/A - intrathecal component	—	R 0	14d	—	—	—	—	2

19 of 19 regimens shown